Abstract
The ability of a lung cancer-associated antigen (LCAA) to provoke specific cutaneous delayed-hypersensitivity reactions has been studied on a group of 59 lung cancer patients. Biological activity of LCAA, monitored by skin testing, was demonstrated in 32% (17 of 53) of lung cancer patients, in 48.0% with limited disease, and in 17.2% with extensive disease. All the responders were in the group of normal reactors to standard recall antigens, if three antigens were used (PPDSK-SD, candida). No correlation was found between biological activity of LCAA and level of immunocompetence evaluated by lymphocyte-blastic transformation with PHA and count of rosette E-forming cells. These studies on the capacity to evoke specific DTH reactions in lung-cancer patients will be extended to the use of assays in vitro in the perspective of a more significant evaluation of immunocompetence levels.
References
Dec 1, 1975·Cancer·J C ReesM C Dodd
Jan 1, 1976·Cancer·J L Vaitukaitis
Dec 15, 1976·International Journal of Cancer. Journal International Du Cancer·J L WeeseJ Djeu
Jul 1, 1976·British Journal of Cancer·B M Jones
Feb 1, 1974·Journal of the National Cancer Institute·A C HollinsheadR B Herberman
Jun 6, 1970·Lancet·A HollinsheadR Herberman
Aug 15, 1974·International Journal of Cancer. Journal International Du Cancer·R VánkyU Nilsonne
Aug 8, 1974·The New England Journal of Medicine·D H CharR B Herberman
Oct 1, 1974·Cancer·A C HollinsheadJ E Harris
Jul 1, 1973·Annals of Surgery·C AlfordR B Heberman
Sep 8, 1972·Science·A C HollinsheadR B Herbeman
Dec 1, 1971·Cancer·T H Stewart, M Orizaga
Sep 1, 1969·Proceedings of the National Academy of Sciences of the United States of America·D M ThomsonP Gold
May 15, 1970·International Journal of Cancer. Journal International Du Cancer·V AndersenI Dissing
Mar 1, 1965·The Journal of Experimental Medicine·P GOLD, S O FREEDMAN